Guardant Health’s research-use-only launch of its early-stage LUNAR cancer assay may be a relatively small step for a company that has fully launched two successful tests for later-stage cancer.
However, Guardant is planning for a proverbial giant leap in the second half of this year, when it rolls out for clinical use the blood-based cancer test the company viewed as something of a moonshot during its development, hence the name.
LUNAR will be used by top-tier academic research networks and biopharmas in studies involving adjuvant therapy decision-making, recurrence monitoring, and screening for . . .